12790 EL CAMINO REAL, SUITE 200, SAN DIEGO, CA
Investor Presentation
Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress
Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson’s Disease
Shareholder votes
Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress
Q2
Q1
FY 2023
Q3
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership